StockMacro
Menu

Summit Therapeutics

$9.95 -41% in 6 monthsMarket cap $8.0B

SMMT on XNAS, Health Care, Summit Therapeutics Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 37% in a month and 40% in a year as the company lost $832.7M over 12 months.

  • BadFree cash flow negative $526.9M over the last 12 months
  • GoodInstitutional holders rose 24% to 294 in one quarter

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Industry
Pharmaceutical preparations (Health Care)
Employees
265
Website
smmttx.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $208.4M.
Quarter to 31 Dec 2021: revenue $251K, net income -$27.1MQuarter to 31 Dec 2021: revenue $251K, net income -$27.1MQuarter to 31 Mar 2022: revenue $250K, net income -$21.4MQuarter to 31 Mar 2022: revenue $250K, net income -$21.4MQuarter to 30 Jun 2022: revenue $235K, net income -$16.8MQuarter to 30 Jun 2022: revenue $235K, net income -$16.8MQuarter to 30 Sep 2022: revenue $220K, net income -$21.4MQuarter to 30 Sep 2022: revenue $220K, net income -$21.4MQuarter to 31 Dec 2022: revenue –, net income -$19.2MQuarter to 31 Mar 2023: revenue $0, net income -$542.4MQuarter to 31 Mar 2023: revenue $0, net income -$542.4MQuarter to 30 Jun 2023: revenue $0, net income -$14.7MQuarter to 30 Jun 2023: revenue $0, net income -$14.7MQuarter to 30 Sep 2023: revenue $0, net income -$21.3MQuarter to 30 Sep 2023: revenue $0, net income -$21.3MQuarter to 31 Dec 2023: revenue $0, net income -$36.6MQuarter to 31 Dec 2023: revenue $0, net income -$36.6MQuarter to 31 Mar 2024: revenue –, net income -$43.5MQuarter to 30 Jun 2024: revenue –, net income -$60.4MQuarter to 30 Sep 2024: revenue $0, net income -$56.3MQuarter to 30 Sep 2024: revenue $0, net income -$56.3MQuarter to 31 Dec 2024: revenue $0, net income -$61.2MQuarter to 31 Dec 2024: revenue $0, net income -$61.2MQuarter to 31 Mar 2025: revenue –, net income -$62.9MQuarter to 30 Jun 2025: revenue –, net income -$565.7MQuarter to 30 Sep 2025: revenue –, net income -$231.8MQuarter to 31 Dec 2025: revenue –, net income -$219.2MQuarter to 31 Mar 2026: revenue –, net income -$189.4MQuarter to 30 Jun 2026: revenue –, net income -$215.7MQuarter to 30 Sep 2026: revenue –, net income -$208.4M
31 Dec 2021RevenueNet incomeNet losstallest bar $565.7M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$208.4M
30 Jun 2026–-$215.7M
31 Mar 2026–-$189.4M
31 Dec 2025–-$219.2M
30 Sep 2025–-$231.8M
30 Jun 2025–-$565.7M
31 Mar 2025–-$62.9M
31 Dec 2024$0-$61.2M
30 Sep 2024$0-$56.3M
30 Jun 2024–-$60.4M
31 Mar 2024–-$43.5M
31 Dec 2023$0-$36.6M
30 Sep 2023$0-$21.3M
30 Jun 2023$0-$14.7M
31 Mar 2023$0-$542.4M
31 Dec 2022–-$19.2M
30 Sep 2022$220K-$21.4M
30 Jun 2022$235K-$16.8M
31 Mar 2022$250K-$21.4M
31 Dec 2021$251K-$27.1M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$832.7M -$921.6M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$1.06 -$1.25
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -220% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$526.9M –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $629.8M $238.6M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$629.8M (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.71
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 14.1 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Summit TherapeuticsSMMT (this company) $8.0Bloss–––
Protagonist TherapeuticsPTGX $7.9B23.214.4+164%62.0%
Rhythm PharmaceuticalsRYTM $7.8Bloss27.7+61%-69.0%
AlkermesALKS $7.6Bloss4.3+15%-0.0%
Praxis Precision MedicinesPRAX $8.4Bloss–––
Kiniksa Pharmaceuticals InternationalKNSA $7.4B67.37.8+58%11.6%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+24%

294 13F filers vs 238

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

17%

134.7M shares held by 13F filers (30 Sep 2026) of 799.8M outstanding (30 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

5.3%

42.3M shares sold short (30 Oct 2026) of 799.8M outstanding (30 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

9.4

42.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+3.3%

40.9M shares sold short in the report before, 42.3M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

49%

49% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 55%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

83

83 articles in the last 7 days; its usual week has 8 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

10×

83 articles in the last 7 days; its usual week has 8.

Price $9.95 on 20 Nov 2026, -40% over 12 months (12-month range $9.95 to $26.38)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $102.2M in the last 12 months (the 12 months before: $22.5M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 8 published in the last 12 months, +167% on the 12 months before.
Revenue per quarter. Revenue $0 in the latest quarter.
Capital spending per quarter. Capital spending $396K in the latest quarter, +458% on a year earlier.
Institutional holders (13F filers). 294 13F filers reported holding it in the latest 13F quarter, +30% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
13 Jun 2026Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 4 filing(s) in 30 days, value_usd total 102.2M)
24 Jan 20258-K and other filingsDirector or officer change
24 Jan 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
25 Sep 20248-K and other filingsPrivate placement of securities (Form D)
30 Jul 2024Sharp changeShort interest spike: short interest spike, 18.6M vs usual 11.1M (2024-07-15); 1.9x the same period a year earlier
16 Jul 2024Sharp changeShort interest spike: short interest spike, 20.3M vs usual 10.8M (2024-06-28); 2.0x the same period a year earlier
2 Jul 2024Sharp changeShort interest spike: short interest spike, 23.4M vs usual 10.8M (2024-06-14); 4.2x the same period a year earlier
27 Jun 20248-K and other filingsDirector or officer change
18 Jun 2024Sharp changeShort interest spike: short interest spike, 21.3M vs usual 10.7M (2024-05-31); 4.6x the same period a year earlier
18 Jun 20248-K and other filingsPrivate placement of securities (Form D)
17 Jun 20248-K and other filingsDirector or officer change
28 May 2024Sharp changeShort interest spike: short interest spike, 22.6M vs usual 10.6M (2024-05-15); 4.3x the same period a year earlier
14 May 2024Sharp changeShort interest spike: short interest spike, 23.4M vs usual 10.6M (2024-04-30); 4.6x the same period a year earlier
30 Apr 2024Sharp changeShort interest spike: short interest spike, 22.9M vs usual 10.4M (2024-04-15); 4.9x the same period a year earlier
16 Apr 2024Sharp changeShort interest spike: short interest spike, 21.8M vs usual 10.1M (2024-03-28); 5.5x the same period a year earlier
11 Apr 20248-K and other filingsDirector or officer change
3 Apr 20248-K and other filingsDirector or officer change
3 Apr 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Apr 2024Sharp changeShort interest spike: short interest spike, 17.0M vs usual 10.0M (2024-03-15); 3.6x the same period a year earlier
12 Mar 2024Sharp changeShort interest spike: short interest spike, 16.0M vs usual 10.0M (2024-02-29); 2.6x the same period a year earlier
17 Oct 2023Sharp changeShort interest spike: short interest spike, 10.7M vs usual 4.9M (2023-09-29); 36.2x the same period a year earlier
16 Oct 20238-K and other filingsDirector or officer change
16 Oct 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 May 2023Sharp changeMany funds opening a new position: many funds opening a new position, 33 vs usual 8.50 (2023-03-31); 5.5x the same period a year earlier
14 Mar 2023Sharp changeShort interest spike: short interest spike, 6.0M vs usual 1.1M (2023-02-28); 5.0x the same period a year earlier
9 Mar 2023Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 420.2M)
28 Feb 2023Sharp changeShort interest spike: short interest spike, 5.4M vs usual 1.1M (2023-02-15); 5.1x the same period a year earlier
14 Feb 2023Sharp changeShort interest spike: short interest spike, 4.3M vs usual 968K (2023-01-31); 6.1x the same period a year earlier
31 Jan 2023Sharp changeShort interest spike: short interest spike, 3.9M vs usual 876K (2023-01-13); 11.0x the same period a year earlier
20 Jan 20238-K and other filingsDirector or officer change
17 Jan 2023Sharp changeShort interest spike: short interest spike, 4.0M vs usual 859K (2022-12-30); 7.7x the same period a year earlier
3 Jan 2023Sharp changeShort interest spike: short interest spike, 5.0M vs usual 803K (2022-12-15); 9.8x the same period a year earlier
27 Dec 20228-K and other filingsDirector or officer change
6 Dec 20228-K and other filingsDirector or officer change
6 Dec 20228-K and other filingsCompleted an acquisition or asset sale
17 Nov 20228-K and other filingsDirector or officer change
3 Oct 20228-K and other filingsDirector or officer change
19 Aug 2022Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 97.7M)
26 Jul 20228-K and other filingsDirector or officer change
1 Jun 20228-K and other filingsDirector or officer change
1 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 May 2022Sharp changeShort interest spike: short interest spike, 1.5M vs usual 586K (2022-05-13); 3.1x the same period a year earlier
29 Mar 2022Sharp changeShort interest spike: short interest spike, 1.2M vs usual 506K (2022-03-15); 3.1x the same period a year earlier
15 Mar 2022Sharp changeShort interest spike: short interest spike, 1.2M vs usual 494K (2022-02-28); 3.3x the same period a year earlier
1 Mar 2022Sharp changeShort interest spike: short interest spike, 1.1M vs usual 486K (2022-02-15); 3.6x the same period a year earlier
12 Jan 20228-K and other filingsDirector or officer change
Insider net buying (open market)
Month from 1 Aug 2022: $97.7M published
Month from 1 Mar 2023: $420.2M published
Month from 1 Oct 2023: $5.0M published
Month from 1 Dec 2023: $55K published
Month from 1 Mar 2024: $786K published
Month from 1 Sep 2025: $12.0M published
Month from 1 Oct 2025: $10.5M published
Month from 1 Jun 2026: $102.2M published
H-1B/E-3 applications certified
Quarter from 1 Jul 2023: 1 published
Quarter from 1 Jan 2024: 2 published
Quarter from 1 Apr 2024: 1 published
Quarter from 1 Jul 2024: 2 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Jan 2025: 2 published
Quarter from 1 Oct 2025: 1 published
Quarter from 1 Jan 2026: 1 published
Quarter from 1 Apr 2026: 2 published
Quarter from 1 Jul 2026: 3 published
Quarter from 1 Oct 2026: 2 published
Revenue per quarter
Quarter ended 31 Dec 2021: $251K, +36% on a year earlier; public on 18 Mar 2022
Quarter ended 31 Mar 2022: $250K, +30% on a year earlier; public on 12 May 2022
Quarter ended 30 Jun 2022: $235K, +312% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $220K, -83% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Mar 2023: $0, -100% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $0, -100% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $0, -100% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $0; public on 21 Feb 2024
Quarter ended 30 Sep 2024: $0; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $0; public on 25 Feb 2025
Capital spending per quarter
Quarter ended 31 Dec 2021: $120K, +140% on a year earlier; public on 18 Mar 2022
Quarter ended 31 Mar 2022: $361K, +826% on a year earlier; public on 12 May 2022
Quarter ended 30 Jun 2022: $293K, +94% on a year earlier; public on 12 Aug 2022
Quarter ended 31 Mar 2023: $53K, -85% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $20K, -93% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $53K; public on 8 Nov 2023
Quarter ended 31 Mar 2024: $4K, -92% on a year earlier; public on 2 May 2024
Quarter ended 30 Jun 2024: $63K, +215% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $58K, +9.4% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $14K; public on 25 Feb 2025
Quarter ended 31 Mar 2025: $422K, +10450% on a year earlier; public on 2 May 2025
Quarter ended 30 Sep 2025: $71K, +22% on a year earlier; public on 21 Oct 2025
Quarter ended 31 Dec 2025: $164K, +1071% on a year earlier; public on 24 Feb 2026
Quarter ended 31 Mar 2026: $245K, -42% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $909K; public on 24 Jul 2026
Quarter ended 30 Sep 2026: $396K, +458% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 49; public on 14 Feb 2022
31 Mar 2022 report: 51; public on 16 May 2022
30 Jun 2022 report: 42; public on 15 Aug 2022
30 Sep 2022 report: 40; public on 14 Nov 2022
31 Dec 2022 report: 56; public on 14 Feb 2023
31 Mar 2023 report: 87; public on 15 May 2023
30 Jun 2023 report: 94; public on 14 Aug 2023
30 Sep 2023 report: 90; public on 14 Nov 2023
31 Dec 2023 report: 89; public on 14 Feb 2024
31 Mar 2024 report: 98; public on 15 May 2024
30 Jun 2024 report: 116; public on 14 Aug 2024
30 Sep 2024 report: 160; public on 14 Nov 2024
31 Dec 2024 report: 197; public on 14 Feb 2025
31 Mar 2025 report: 206; public on 15 May 2025
30 Jun 2025 report: 228; public on 14 Aug 2025
30 Sep 2025 report: 226; public on 14 Nov 2025
31 Dec 2025 report: 200; public on 17 Feb 2026
31 Mar 2026 report: 219; public on 15 May 2026
30 Jun 2026 report: 238; public on 14 Aug 2026
30 Sep 2026 report: 294; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $100.0M (12 Jun 2026), 28× its normal reading; higher than 93% of its own history.
  • Clustered insider buying: had 3 insiders buy $102.2M of its shares on the open market within 30 days (4 filings) Public on 13 Jun 2026.
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 8 published in the last 12 months, +167% on the 12 months before.
  • Revenue per quarter: Revenue $0 in the latest quarter.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 28 insider trades

No trades in the last 90 days; the latest was filed 12 Jun 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
12 Jun 2026Robert W DugganCo-Chief Executive OfficerBuy3,810,000$13.12$50.0MForm 4
12 Jun 2026Mahkam ZanganehCo-Chief Executive OfficerBuy3,810,000$13.12$50.0MForm 4
4 Jun 2026Robert W DugganCo-Chief Executive OfficerBuy100,000$14.60$1.5MForm 4
4 Jun 2026Manmeet Singh SoniCOO and CFOBuy50,000$14.45$722KForm 4
23 Oct 2025Yu XiaDirectorBuy533,617$18.74$10.0MForm 4
23 Oct 2025Robert W DugganCo-Chief Executive OfficerBuy26,680$18.74$500KForm 4
11 Sep 2025Mahkam ZanganehCo-Chief Executive OfficerBuy338,394$17.69$6.0MForm 4
11 Sep 2025Robert W DugganCo-Chief Executive OfficerBuy338,394$17.69$6.0MForm 4

294 institutions reported shares at the end of Q3 2026, 17% of the shares outstanding; 84 opened a position, 34 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Baker Bros. Advisors LP32.8M4.10%$554.4MNo change
BlackRock, Inc.10.4M1.30%$175.3M+835K+8.8%
FMR LLC (Fidelity)8.1M1.02%$137.6M-1.9M-19%
Vanguard Capital Management LLC7.2M0.90%$122.3M+1.5M+26%
Vanguard Portfolio Management LLC6.7M0.84%$113.6M+1.7M+33%
State Street Corp6.1M0.76%$103.0M-3.4M-36%
T. Rowe Price Associates Inc5.3M0.66%+1.4M+36%
Citadel Advisors LLC3.8M0.47%$64.0M+2.1M+119%
Geode Capital Management, LLC3.5M0.44%$59.0M+62K+1.8%
Kynam Capital Management, LP3.0M0.38%$50.7M+1.8M+150%

Company events

All 48 company events

In 12 months: 2 major agreements. Results releases and routine reports are left out.

FiledWhat happenedSource
28 Sep 2026Signed a major agreementSame filing: sold shares privately, changed its bylaws or fiscal year8-K
23 Jul 2026Signed a major agreement8-K
22 Oct 2025Signed a major agreementSame filing: sold shares privately8-K
11 Aug 2025Signed a major agreement8-K
20 Jun 2025Signed a major agreement8-K
24 Jan 2025Director or officer change8-K
25 Sep 2024Private placement of securities (Form D)$235.0M sold of $235.0M offeredD
12 Sep 2024Signed a major agreementSame filing: sold shares privately8-K

Reported lobbying spend: $30K in Q2 2020. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
30 Jun 2021EndedThe KPM Group DC LLCfor Summit Therapeutics PLCNot statedFiling
15 Apr 2020NewThe KPM Group DC LLCfor Summit Therapeutics PLCCOVID -19 Stimulus Package (domestic manufacturing)PharmacyFiling

The 5 newest of 462 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

9 Mar 2023confirmed

Confirmed across sources Insiders and Short interest and volume

Summit Therapeutics (SMMT): had 5.4M shares sold short in the 15 Feb 2023 report, 5.1× the same report last year, while it had 3 insiders buy $420.2M of its shares on the open market within 30 days (3 filings). Two unrelated kinds of activity within 28 days.

  • Short interest and volume: Short interest spike, became public on 10 Feb 2023
  • Short interest and volume: Short interest spike, became public on 28 Feb 2023
  • Insiders: Clustered insider buying, became public on 9 Mar 2023
  • Short interest and volume: Short interest spike, became public on 10 Mar 2023
2022-02-15: 1.1M2022-02-28: 1.2M2022-03-15: 1.2M2022-03-31: 1.1M2022-04-14: 1.1M2022-04-29: 1.4M2022-05-13: 1.5M2022-05-31: 1.1M2022-06-15: 1.1M2022-06-30: 761K2022-07-15: 879K2022-07-29: 872K2022-08-15: 846K2022-08-31: 352K2022-09-15: 203K2022-09-30: 295K2022-10-14: 375K2022-10-31: 278K2022-11-15: 261K2022-11-30: 235K2022-12-15: 5.0M2022-12-30: 4.0M2023-01-13: 3.9M2023-01-31: 4.3M2023-02-15: 5.4M
The 15 Feb 2023 report against the 24 reports before it. this reportearliernormal: 1.1M
See the evidence (4 changes)

Short interest and volume: Short interest spike became public on 10 Feb 2023

Summit Therapeutics had 4.3M shares sold short in the 31 Jan 2023 report, 6.1× the same report last year.

This period
4.3M (the 31 Jan 2023 report)
Normal report (median of 24 earlier)
968K
Typical spread (median absolute deviation)
329K
How far from its usual level
+6.8
Same report last year
706K
History used
1,859 days
2022-01-31: 706K2022-02-15: 1.1M2022-02-28: 1.2M2022-03-15: 1.2M2022-03-31: 1.1M2022-04-14: 1.1M2022-04-29: 1.4M2022-05-13: 1.5M2022-05-31: 1.1M2022-06-15: 1.1M2022-06-30: 761K2022-07-15: 879K2022-07-29: 872K2022-08-15: 846K2022-08-31: 352K2022-09-15: 203K2022-09-30: 295K2022-10-14: 375K2022-10-31: 278K2022-11-15: 261K2022-11-30: 235K2022-12-15: 5.0M2022-12-30: 4.0M2023-01-13: 3.9M2023-01-31: 4.3M
the 31 Jan 2023 report24 earlier reportsnormal: 968K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 Feb 2023

Summit Therapeutics had 5.4M shares sold short in the 15 Feb 2023 report, 5.1× the same report last year.

This period
5.4M (the 15 Feb 2023 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
384K
How far from its usual level
+7.6
Same report last year
1.1M
History used
1,874 days
2022-02-15: 1.1M2022-02-28: 1.2M2022-03-15: 1.2M2022-03-31: 1.1M2022-04-14: 1.1M2022-04-29: 1.4M2022-05-13: 1.5M2022-05-31: 1.1M2022-06-15: 1.1M2022-06-30: 761K2022-07-15: 879K2022-07-29: 872K2022-08-15: 846K2022-08-31: 352K2022-09-15: 203K2022-09-30: 295K2022-10-14: 375K2022-10-31: 278K2022-11-15: 261K2022-11-30: 235K2022-12-15: 5.0M2022-12-30: 4.0M2023-01-13: 3.9M2023-01-31: 4.3M2023-02-15: 5.4M
the 15 Feb 2023 report24 earlier reportsnormal: 1.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Insiders: Clustered insider buying became public on 9 Mar 2023

Summit Therapeutics had 3 insiders buy $420.2M of its shares on the open market within 30 days (3 filings).

Independent buyers
3
Purchase filings (Form 4, code P)
3
Total bought
$420.2M
Window
7 Feb 2023 to 9 Mar 2023

Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Short interest and volume: Short interest spike became public on 10 Mar 2023

Summit Therapeutics had 6.0M shares sold short in the 28 Feb 2023 report, 5.0× the same report last year.

This period
6.0M (the 28 Feb 2023 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
577K
How far from its usual level
+5.7
Same report last year
1.2M
History used
1,887 days
2022-02-28: 1.2M2022-03-15: 1.2M2022-03-31: 1.1M2022-04-14: 1.1M2022-04-29: 1.4M2022-05-13: 1.5M2022-05-31: 1.1M2022-06-15: 1.1M2022-06-30: 761K2022-07-15: 879K2022-07-29: 872K2022-08-15: 846K2022-08-31: 352K2022-09-15: 203K2022-09-30: 295K2022-10-14: 375K2022-10-31: 278K2022-11-15: 261K2022-11-30: 235K2022-12-15: 5.0M2022-12-30: 4.0M2023-01-13: 3.9M2023-01-31: 4.3M2023-02-15: 5.4M2023-02-28: 6.0M
the 28 Feb 2023 report24 earlier reportsnormal: 1.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 13 Jun 2026Insiders change

    had 3 insiders buy $102.2M of its shares on the open market within 30 days (4 filings).

    Who bought: Soni Manmeet Singh, Duggan Robert W, Zanganeh Mahkam.

    See the evidence (4 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    4
    Total bought
    $102.2M
    Window
    14 May 2026 to 13 Jun 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  2. 13 Jun 2026Insiders record

    DUGGAN ROBERT W (Co-Chief Executive Officer) bought 3,810,000 shares of SMMT ($50.0M) (dated 12 Jun 2026)

  3. 13 Jun 2026Insiders record

    Zanganeh Mahkam (Co-Chief Executive Officer) bought 3,810,000 shares of SMMT ($50.0M) (dated 12 Jun 2026)

  4. 5 Jun 2026Insiders record

    Zanganeh Mahkam (Co-Chief Executive Officer) bought 100,000 shares of SMMT [same transaction as an earlier filing] (dated 4 Jun 2026)

  5. 5 Jun 2026Insiders record

    DUGGAN ROBERT W (Co-Chief Executive Officer) bought 100,000 shares of SMMT ($1.5M) (dated 4 Jun 2026)

  6. 5 Jun 2026Insiders record

    Soni Manmeet Singh (COO and CFO) bought 50,000 shares of SMMT ($722,250) (dated 4 Jun 2026)

  7. 24 Oct 2025Insiders record

    Zanganeh Mahkam (Co-Chief Executive Officer) bought 26,680 shares of SMMT [same transaction as an earlier filing] (dated 23 Oct 2025)

  8. 24 Oct 2025Insiders record

    Xia Yu (director) bought 533,617 shares of SMMT ($10.0M) (dated 23 Oct 2025)

  9. 24 Oct 2025Insiders record

    DUGGAN ROBERT W (Co-Chief Executive Officer) bought 26,680 shares of SMMT ($499,983) (dated 23 Oct 2025)

  10. 12 Sep 2025Insiders record

    Zanganeh Mahkam (Co-Chief Executive Officer) bought 338,394 shares of SMMT ($6.0M) (dated 11 Sep 2025)

  11. 12 Sep 2025Insiders record

    DUGGAN ROBERT W (Co-Chief Executive Officer) bought 338,394 shares of SMMT ($6.0M) (dated 11 Sep 2025)

  12. 24 Jan 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 24 Jan 2025Filings record

    Director or officer change

  14. 25 Sep 2024Filings record

    Private placement of securities (Form D)

  15. 25 Jul 2024Short interest and volume change

    had 18.6M shares sold short in the 15 Jul 2024 report, 1.9× the same report last year.

    Same report last year: 10.0M; its normal report is 11.1M.

    See the evidence
    This period
    18.6M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    11.1M
    Typical spread (median absolute deviation)
    1.4M
    How far from its usual level
    +3.6
    Same report last year
    10.0M
    History used
    2,390 days
    2023-07-14: 10.0M2023-07-31: 10.8M2023-08-15: 11.6M2023-08-31: 10.5M2023-09-15: 10.6M2023-09-29: 10.7M2023-10-13: 10.7M2023-10-31: 9.5M2023-11-15: 10.0M2023-11-30: 10.0M2023-12-15: 9.4M2023-12-29: 9.8M2024-01-12: 10.8M2024-01-31: 11.3M2024-02-15: 12.8M2024-02-29: 16.0M2024-03-15: 17.0M2024-03-28: 21.8M2024-04-15: 22.9M2024-04-30: 23.4M2024-05-15: 22.6M2024-05-31: 21.3M2024-06-14: 23.4M2024-06-28: 20.3M2024-07-15: 18.6M
    the 15 Jul 2024 report24 earlier reportsnormal: 11.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 11 Jul 2024Short interest and volume change

    had 20.3M shares sold short in the 28 Jun 2024 report, 2.0× the same report last year.

    Same report last year: 10.2M; its normal report is 10.8M.

    See the evidence
    This period
    20.3M (the 28 Jun 2024 report)
    Normal report (median of 24 earlier)
    10.8M
    Typical spread (median absolute deviation)
    930K
    How far from its usual level
    +6.9
    Same report last year
    10.2M
    History used
    2,373 days
    2023-06-30: 10.2M2023-07-14: 10.0M2023-07-31: 10.8M2023-08-15: 11.6M2023-08-31: 10.5M2023-09-15: 10.6M2023-09-29: 10.7M2023-10-13: 10.7M2023-10-31: 9.5M2023-11-15: 10.0M2023-11-30: 10.0M2023-12-15: 9.4M2023-12-29: 9.8M2024-01-12: 10.8M2024-01-31: 11.3M2024-02-15: 12.8M2024-02-29: 16.0M2024-03-15: 17.0M2024-03-28: 21.8M2024-04-15: 22.9M2024-04-30: 23.4M2024-05-15: 22.6M2024-05-31: 21.3M2024-06-14: 23.4M2024-06-28: 20.3M
    the 28 Jun 2024 report24 earlier reportsnormal: 10.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 27 Jun 2024Short interest and volume change

    had 23.4M shares sold short in the 14 Jun 2024 report, 4.2× the same report last year.

    Same report last year: 5.6M; its normal report is 10.8M.

    See the evidence
    This period
    23.4M (the 14 Jun 2024 report)
    Normal report (median of 24 earlier)
    10.8M
    Typical spread (median absolute deviation)
    897K
    How far from its usual level
    +9.5
    Same report last year
    5.6M
    History used
    2,359 days
    2023-06-15: 5.6M2023-06-30: 10.2M2023-07-14: 10.0M2023-07-31: 10.8M2023-08-15: 11.6M2023-08-31: 10.5M2023-09-15: 10.6M2023-09-29: 10.7M2023-10-13: 10.7M2023-10-31: 9.5M2023-11-15: 10.0M2023-11-30: 10.0M2023-12-15: 9.4M2023-12-29: 9.8M2024-01-12: 10.8M2024-01-31: 11.3M2024-02-15: 12.8M2024-02-29: 16.0M2024-03-15: 17.0M2024-03-28: 21.8M2024-04-15: 22.9M2024-04-30: 23.4M2024-05-15: 22.6M2024-05-31: 21.3M2024-06-14: 23.4M
    the 14 Jun 2024 report24 earlier reportsnormal: 10.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 27 Jun 2024Filings record

    Director or officer change

  19. 18 Jun 2024Filings record

    Private placement of securities (Form D)

  20. 17 Jun 2024Filings record

    Director or officer change

  21. 12 Jun 2024Short interest and volume change

    had 21.3M shares sold short in the 31 May 2024 report, 4.6× the same report last year.

    Same report last year: 4.6M; its normal report is 10.7M.

    See the evidence
    This period
    21.3M (the 31 May 2024 report)
    Normal report (median of 24 earlier)
    10.7M
    Typical spread (median absolute deviation)
    897K
    How far from its usual level
    +7.9
    Same report last year
    4.6M
    History used
    2,345 days
    2023-05-31: 4.6M2023-06-15: 5.6M2023-06-30: 10.2M2023-07-14: 10.0M2023-07-31: 10.8M2023-08-15: 11.6M2023-08-31: 10.5M2023-09-15: 10.6M2023-09-29: 10.7M2023-10-13: 10.7M2023-10-31: 9.5M2023-11-15: 10.0M2023-11-30: 10.0M2023-12-15: 9.4M2023-12-29: 9.8M2024-01-12: 10.8M2024-01-31: 11.3M2024-02-15: 12.8M2024-02-29: 16.0M2024-03-15: 17.0M2024-03-28: 21.8M2024-04-15: 22.9M2024-04-30: 23.4M2024-05-15: 22.6M2024-05-31: 21.3M
    the 31 May 2024 report24 earlier reportsnormal: 10.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 25 May 2024Short interest and volume change

    had 22.6M shares sold short in the 15 May 2024 report, 4.3× the same report last year.

    Same report last year: 5.2M; its normal report is 10.6M.

    See the evidence
    This period
    22.6M (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    10.6M
    Typical spread (median absolute deviation)
    897K
    How far from its usual level
    +9.0
    Same report last year
    5.2M
    History used
    2,329 days
    2023-05-15: 5.2M2023-05-31: 4.6M2023-06-15: 5.6M2023-06-30: 10.2M2023-07-14: 10.0M2023-07-31: 10.8M2023-08-15: 11.6M2023-08-31: 10.5M2023-09-15: 10.6M2023-09-29: 10.7M2023-10-13: 10.7M2023-10-31: 9.5M2023-11-15: 10.0M2023-11-30: 10.0M2023-12-15: 9.4M2023-12-29: 9.8M2024-01-12: 10.8M2024-01-31: 11.3M2024-02-15: 12.8M2024-02-29: 16.0M2024-03-15: 17.0M2024-03-28: 21.8M2024-04-15: 22.9M2024-04-30: 23.4M2024-05-15: 22.6M
    the 15 May 2024 report24 earlier reportsnormal: 10.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 10 May 2024Short interest and volume change

    had 23.4M shares sold short in the 30 Apr 2024 report, 4.6× the same report last year.

    Same report last year: 5.1M; its normal report is 10.6M.

    See the evidence
    This period
    23.4M (the 30 Apr 2024 report)
    Normal report (median of 24 earlier)
    10.6M
    Typical spread (median absolute deviation)
    897K
    How far from its usual level
    +9.7
    Same report last year
    5.1M
    History used
    2,314 days
    2023-04-28: 5.1M2023-05-15: 5.2M2023-05-31: 4.6M2023-06-15: 5.6M2023-06-30: 10.2M2023-07-14: 10.0M2023-07-31: 10.8M2023-08-15: 11.6M2023-08-31: 10.5M2023-09-15: 10.6M2023-09-29: 10.7M2023-10-13: 10.7M2023-10-31: 9.5M2023-11-15: 10.0M2023-11-30: 10.0M2023-12-15: 9.4M2023-12-29: 9.8M2024-01-12: 10.8M2024-01-31: 11.3M2024-02-15: 12.8M2024-02-29: 16.0M2024-03-15: 17.0M2024-03-28: 21.8M2024-04-15: 22.9M2024-04-30: 23.4M
    the 30 Apr 2024 report24 earlier reportsnormal: 10.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 25 Apr 2024Short interest and volume change

    had 22.9M shares sold short in the 15 Apr 2024 report, 4.9× the same report last year.

    Same report last year: 4.7M; its normal report is 10.4M.

    See the evidence
    This period
    22.9M (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    10.4M
    Typical spread (median absolute deviation)
    910K
    How far from its usual level
    +9.3
    Same report last year
    4.7M
    History used
    2,299 days
    2023-04-14: 4.7M2023-04-28: 5.1M2023-05-15: 5.2M2023-05-31: 4.6M2023-06-15: 5.6M2023-06-30: 10.2M2023-07-14: 10.0M2023-07-31: 10.8M2023-08-15: 11.6M2023-08-31: 10.5M2023-09-15: 10.6M2023-09-29: 10.7M2023-10-13: 10.7M2023-10-31: 9.5M2023-11-15: 10.0M2023-11-30: 10.0M2023-12-15: 9.4M2023-12-29: 9.8M2024-01-12: 10.8M2024-01-31: 11.3M2024-02-15: 12.8M2024-02-29: 16.0M2024-03-15: 17.0M2024-03-28: 21.8M2024-04-15: 22.9M
    the 15 Apr 2024 report24 earlier reportsnormal: 10.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 11 Apr 2024Filings record

    Director or officer change

  26. 10 Apr 2024Short interest and volume change

    had 21.8M shares sold short in the 28 Mar 2024 report, 5.5× the same report last year.

    Same report last year: 3.9M; its normal report is 10.1M.

    See the evidence
    This period
    21.8M (the 28 Mar 2024 report)
    Normal report (median of 24 earlier)
    10.1M
    Typical spread (median absolute deviation)
    692K
    How far from its usual level
    +11.4
    Same report last year
    3.9M
    History used
    2,281 days
    2023-03-31: 3.9M2023-04-14: 4.7M2023-04-28: 5.1M2023-05-15: 5.2M2023-05-31: 4.6M2023-06-15: 5.6M2023-06-30: 10.2M2023-07-14: 10.0M2023-07-31: 10.8M2023-08-15: 11.6M2023-08-31: 10.5M2023-09-15: 10.6M2023-09-29: 10.7M2023-10-13: 10.7M2023-10-31: 9.5M2023-11-15: 10.0M2023-11-30: 10.0M2023-12-15: 9.4M2023-12-29: 9.8M2024-01-12: 10.8M2024-01-31: 11.3M2024-02-15: 12.8M2024-02-29: 16.0M2024-03-15: 17.0M2024-03-28: 21.8M
    the 28 Mar 2024 report24 earlier reportsnormal: 10.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 3 Apr 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  28. 3 Apr 2024Filings record

    Director or officer change

  29. 28 Mar 2024Insiders record

    Dhingra Ankur (Chief Financial Officer) bought 100,000 shares of SMMT ($375,000) (dated 27 Mar 2024)

  30. 28 Mar 2024Insiders record

    Zanganeh Mahkam (Chief Executive Officer) bought 110,321 shares of SMMT ($411,094) (dated 27 Mar 2024)

  31. 27 Mar 2024Short interest and volume change

    had 17.0M shares sold short in the 15 Mar 2024 report, 3.6× the same report last year.

    Same report last year: 4.7M; its normal report is 10.0M.

    See the evidence
    This period
    17.0M (the 15 Mar 2024 report)
    Normal report (median of 24 earlier)
    10.0M
    Typical spread (median absolute deviation)
    781K
    How far from its usual level
    +6.0
    Same report last year
    4.7M
    History used
    2,268 days
    2023-03-15: 4.7M2023-03-31: 3.9M2023-04-14: 4.7M2023-04-28: 5.1M2023-05-15: 5.2M2023-05-31: 4.6M2023-06-15: 5.6M2023-06-30: 10.2M2023-07-14: 10.0M2023-07-31: 10.8M2023-08-15: 11.6M2023-08-31: 10.5M2023-09-15: 10.6M2023-09-29: 10.7M2023-10-13: 10.7M2023-10-31: 9.5M2023-11-15: 10.0M2023-11-30: 10.0M2023-12-15: 9.4M2023-12-29: 9.8M2024-01-12: 10.8M2024-01-31: 11.3M2024-02-15: 12.8M2024-02-29: 16.0M2024-03-15: 17.0M
    the 15 Mar 2024 report24 earlier reportsnormal: 10.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 12 Mar 2024Short interest and volume change

    had 16.0M shares sold short in the 29 Feb 2024 report, 2.6× the same report last year.

    Same report last year: 6.0M; its normal report is 10.0M.

    See the evidence
    This period
    16.0M (the 29 Feb 2024 report)
    Normal report (median of 24 earlier)
    10.0M
    Typical spread (median absolute deviation)
    805K
    How far from its usual level
    +5.0
    Same report last year
    6.0M
    History used
    2,253 days
    2023-02-28: 6.0M2023-03-15: 4.7M2023-03-31: 3.9M2023-04-14: 4.7M2023-04-28: 5.1M2023-05-15: 5.2M2023-05-31: 4.6M2023-06-15: 5.6M2023-06-30: 10.2M2023-07-14: 10.0M2023-07-31: 10.8M2023-08-15: 11.6M2023-08-31: 10.5M2023-09-15: 10.6M2023-09-29: 10.7M2023-10-13: 10.7M2023-10-31: 9.5M2023-11-15: 10.0M2023-11-30: 10.0M2023-12-15: 9.4M2023-12-29: 9.8M2024-01-12: 10.8M2024-01-31: 11.3M2024-02-15: 12.8M2024-02-29: 16.0M
    the 29 Feb 2024 report24 earlier reportsnormal: 10.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 14 Dec 2023Insiders record

    Dhingra Ankur (Chief Financial Officer) bought 20,400 shares of SMMT ($44,254) (dated 13 Dec 2023)

  34. 14 Dec 2023Insiders record

    Zanganeh Mahkam (Chief Executive Officer) bought 5,000 shares of SMMT ($10,350) (dated 13 Dec 2023)

  35. 17 Oct 2023Insiders record

    Soni Manmeet Singh (Chief Operating Officer) bought 2,976,190 shares of SMMT ($5.0M) (dated 16 Oct 2023)

  36. 16 Oct 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 16 Oct 2023Filings record

    Director or officer change

  38. 12 Oct 2023Short interest and volume change

    had 10.7M shares sold short in the 29 Sep 2023 report, 36× the same report last year.

    Same report last year: 295K; its normal report is 4.9M.

    See the evidence
    This period
    10.7M (the 29 Sep 2023 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    1.1M
    How far from its usual level
    +3.7
    Same report last year
    295K
    History used
    2,100 days
    2022-09-30: 295K2022-10-14: 375K2022-10-31: 278K2022-11-15: 261K2022-11-30: 235K2022-12-15: 5.0M2022-12-30: 4.0M2023-01-13: 3.9M2023-01-31: 4.3M2023-02-15: 5.4M2023-02-28: 6.0M2023-03-15: 4.7M2023-03-31: 3.9M2023-04-14: 4.7M2023-04-28: 5.1M2023-05-15: 5.2M2023-05-31: 4.6M2023-06-15: 5.6M2023-06-30: 10.2M2023-07-14: 10.0M2023-07-31: 10.8M2023-08-15: 11.6M2023-08-31: 10.5M2023-09-15: 10.6M2023-09-29: 10.7M
    the 29 Sep 2023 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 15 May 2023Institutional holdings change

    saw 33 13F filers open a new position in the quarter ended 31 Mar 2023, 5.5× the same quarter last year.

    Same quarter last year: 6; its normal quarter is 8.5.

    See the evidence
    This period
    33 (the quarter ended 31 Mar 2023)
    Normal quarter (median of 8 earlier)
    8.5
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +4.1
    Same quarter last year
    6
    History used
    2,922 days
    2021-03-31: 82021-06-30: 232021-09-30: 42021-12-31: 32022-03-31: 62022-06-30: 122022-09-30: 92022-12-31: 212023-03-31: 33
    the quarter ended 31 Mar 20238 earlier quartersnormal: 8.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  40. 14 Mar 2023Insiders record

    Zanganeh Mahkam (Co-CEO & President) bought 23,527,044 shares of SMMT ($17.6M) [amended] (dated 13 Mar 2023)

Showing the newest 40 of 97 entries; narrow the window or the kind of data to see older ones.

Not listed: 142 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001599298
Ticker
SMMT
Domain
smmttx.com
Employer name
Summit Therapeutics, Inc. (1 unverified)
Hq location
FL|MIAMI|33131 (1 unverified)
Lobbying client
summit therapeutics
Name
Discuva Limited, Summit Corp plc, Summit International Holdings Limited (Cayman Islands), Summit (Oxford) Limited and 5 more
Uei
T3JZAH1DVLC9
  • DOL H-1B labor condition applications and PERM certifications90 data points19 Jun 2023 to 31 Aug 2026
  • Federal lobbying disclosures (LDA)2 records, 11 data points15 Apr 2020 to 30 Jun 2021
  • SEC Form 13F institutional holdings423 data points31 Mar 2015 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)171 records11 May 2016 to 18 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)406 data points31 Jan 2018 to 30 Oct 2026
  • SEC Form 4 insider transactions28 records, 56 data points10 Nov 2020 to 12 Jun 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4172 data points1 Aug 2018 to 20 Nov 2026